{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:19:06Z","timestamp":1781018346740,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Randomized controlled trials (RCTs) have shown an antidepressant effect of glabellar botulinum toxin (BoNT) injections. In the FDA Adverse Event Reporting System (FAERS) database, BoNT injection is associated with reduced incidence rates of depression across various non-psychiatric indications, which confirms the previous findings independently of specific expectations to an antidepressant effect of BoNT. The rationale of using BoNT to treat depression is to interrupt proprioceptive body feedback that may reinforce negative emotions. Negative emotions also occur in other mental disorders, suggesting a transdiagnostic therapeutic potential of BoNT in psychiatry. Here we report an analysis of the FAERS database, in which we found that, compared to alternative treatments, BoNT injections were associated with lower incidence of anxiety symptoms and related disorders. Among seven indications\/injection sites, we found this protective effect of BoNT in cosmetic use\/facial muscles, migraine\/facial and head muscles, spasms and spasticity\/upper and lower limbs, torticollis and neck pain\/neck muscles, and sialorrhea\/parotid and submandibular glands (reporting odds ratios 0.79\u20130.27). These findings are encouraging for possible future RCTs on the use of BoNT as a treatment for anxiety and related disorders.<\/jats:p>","DOI":"10.1038\/s41598-021-03713-x","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T11:03:53Z","timestamp":1640084633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety"],"prefix":"10.1038","volume":"11","author":[{"given":"M. Axel","family":"Wollmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tigran","family":"Makunts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tillmann H. C.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Abagyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"3713_CR1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","volume":"46","author":"MA Wollmer","year":"2012","unstructured":"Wollmer, M. A. et al. Facing depression with botulinum toxin: A randomized controlled trial. J. Psychiatr. Res. 46, 574\u2013581 (2012).","journal-title":"J. Psychiatr. Res."},{"key":"3713_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.11.006","volume":"52","author":"E Finzi","year":"2014","unstructured":"Finzi, E. & Rosenthal, N. E. Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial. J. Psychiatr. Res. 52, 1\u20136 (2014).","journal-title":"J. Psychiatr. Res."},{"key":"3713_CR3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4088\/JCP.13m08845","volume":"75","author":"M Magid","year":"2014","unstructured":"Magid, M. et al. Treatment of major depressive disorder using botulinum toxin A: A 24-week randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry. 75, 837\u2013844 (2014).","journal-title":"J. Clin. Psychiatry."},{"key":"3713_CR4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0035-1559621","volume":"48","author":"M Magid","year":"2015","unstructured":"Magid, M. et al. Treating depression with botulinum toxin: A pooled analysis of randomized controlled trials. Pharmacopsychiatry 48, 205\u2013210 (2015).","journal-title":"Pharmacopsychiatry"},{"key":"3713_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YIC.0000000000000290","volume":"35","author":"MF Brin","year":"2020","unstructured":"Brin, M. F. et al. OnabotulinumtoxinA for the treatment of major depressive disorder: A phase 2 randomized, double-blind, placebo-controlled trial in adult females. Int. Clin. Psychopharmacol. 35, 19\u201328 (2020).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"3713_CR6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jpsychires.2021.01.016","volume":"135","author":"J Schulze","year":"2021","unstructured":"Schulze, J. et al. Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis. J. Psychiatr. Res. 135, 332\u2013340 (2021).","journal-title":"J. Psychiatr. Res."},{"key":"3713_CR7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41598-017-01590-x","volume":"7","author":"IV Cohen","year":"2017","unstructured":"Cohen, I. V., Makunts, T., Atayee, R. & Abagyan, R. Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. Sci. Rep. 7, 1450 (2017).","journal-title":"Sci. Rep."},{"key":"3713_CR8","doi-asserted-by":"crossref","first-page":"12851","DOI":"10.1038\/s41598-020-69773-7","volume":"10","author":"T Makunts","year":"2020","unstructured":"Makunts, T., Wollmer, M. A. & Abagyan, R. Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. Sci Rep. 10, 12851 (2020).","journal-title":"Sci Rep."},{"key":"3713_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jpsychires.2016.06.009","volume":"80","author":"E Finzi","year":"2016","unstructured":"Finzi, E. & Rosenthal, N. E. Emotional proprioception: Treatment of depression with afferent facial feedback. J. Psychiatr. Res. 80, 93\u201396 (2016).","journal-title":"J. Psychiatr. Res."},{"key":"3713_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/228276","volume":"92","author":"PA Thoits","year":"1985","unstructured":"Thoits, P. A. Self-labeling processes in mental illness: The role of emotional deviance. Am. J. Sociol. 92, 221\u2013249 (1985).","journal-title":"Am. J. Sociol."},{"key":"3713_CR11","unstructured":"Ritchie H. & Roser M. Mental Health. OurWorldInData.org. https:\/\/ourworldindata.org\/mental-health (2018)."},{"key":"3713_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.janxdis.2006.08.001","volume":"21","author":"A Conrad","year":"2007","unstructured":"Conrad, A. & Roth, W. T. Muscle relaxation therapy for anxiety disorders: It works but how?. J. Anxiety Disord. 21, 243\u2013264 (2007).","journal-title":"J. Anxiety Disord."},{"key":"3713_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpr.2009.08.008","volume":"30","author":"K Domschke","year":"2010","unstructured":"Domschke, K., Stevens, S., Pfleiderer, B. & Gerlach, A. L. Interoceptive sensitivity in anxiety and anxiety disorders: An overview and integration of neurobiological findings. Clin. Psychol. Rev. 30, 1\u201311 (2010).","journal-title":"Clin. Psychol. Rev."},{"key":"3713_CR14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1017\/S0033291717003099","volume":"48","author":"J Montero-Marin","year":"2018","unstructured":"Montero-Marin, J., Garcia-Campayo, J., L\u00f3pez-Montoyo, A., Zabaleta-Del-Olmo, E. & Cuijpers, P. Is cognitive-behavioural therapy more effective than relaxation therapy in the treatment of anxiety disorders? A meta-analysis. Psychol. Med. 48, 1427\u20131436 (2018).","journal-title":"Psychol. Med."},{"key":"3713_CR15","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3389\/fpsyg.2019.02907","volume":"10","author":"MS Tarsha","year":"2020","unstructured":"Tarsha, M. S., Park, S. & Tortora, S. Body-centered interventions for psychopathological conditions: A review. Front. Psychol. 10, 2907 (2020).","journal-title":"Front. Psychol."},{"key":"3713_CR16","doi-asserted-by":"crossref","first-page":"e0242578","DOI":"10.1371\/journal.pone.0242578","volume":"15","author":"F Weineck","year":"2020","unstructured":"Weineck, F., Schultchen, D., Hauke, G., Messner, M. & Pollatos, O. Using bodily postures to reduce anxiety and improve interoception: A comparison between powerful and neutral poses. PLoS ONE 15, e0242578 (2020).","journal-title":"PLoS ONE"},{"key":"3713_CR17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/JCP.0000000000001066","volume":"39","author":"E Finzi","year":"2019","unstructured":"Finzi, E. & Rosenthal, N. E. Botulinum toxin therapy of social anxiety disorder: A case series. J. Clin. Psychopharmacol. 39, 410\u2013412 (2019).","journal-title":"J. Clin. Psychopharmacol."},{"key":"3713_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1473-2165.2009.00419.x","volume":"8","author":"MB Lewis","year":"2009","unstructured":"Lewis, M. B. & Bowler, P. J. Botulinum toxin cosmetic therapy correlates with a more positive mood. J. Cosmet. Dermatol. 8, 24\u201326 (2009).","journal-title":"J. Cosmet. Dermatol."},{"key":"3713_CR19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/da.10039","volume":"16","author":"E Moraru","year":"2002","unstructured":"Moraru, E. et al. Relation between depression and anxiety in dystonic patients: Implications for clinical management. Depress. Anxiety 16, 100\u2013103 (2002).","journal-title":"Depress. Anxiety"},{"key":"3713_CR20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2133.2004.06334.x","volume":"152","author":"A Weber","year":"2005","unstructured":"Weber, A. et al. Psychosocial aspects of patients with focal hyperhidrosis: Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br. J. Dermatol. 152, 342\u2013345 (2005).","journal-title":"Br. J. Dermatol."},{"key":"3713_CR21","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s10072-016-2665-z","volume":"37","author":"BE Demiryurek","year":"2016","unstructured":"Demiryurek, B. E. et al. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol. Sci. 37, 1779\u20131784 (2016).","journal-title":"Neurol. Sci."},{"key":"3713_CR22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/1346-8138.13291","volume":"43","author":"A Shayesteh","year":"2016","unstructured":"Shayesteh, A., Boman, J., Janlert, U., Brulin, C. & Nylander, E. Primary hyperhidrosis: Implications on symptoms, daily life, health and alcohol consumption when treated with botulinum toxin. J. Dermatol. 43, 928\u2013933 (2016).","journal-title":"J. Dermatol."},{"key":"3713_CR23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s13760-016-0634-1","volume":"116","author":"S Tomic","year":"2016","unstructured":"Tomic, S. et al. Cervical dystonia and quality of life. Acta Neurol. Belg. 116, 589\u2013592 (2016).","journal-title":"Acta Neurol. Belg."},{"key":"3713_CR24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/NDT.S181820","volume":"15","author":"H Dong","year":"2018","unstructured":"Dong, H., Fan, S., Luo, Y. & Peng, B. Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm. Neuropsychiatr. Dis. Treat. 15, 33\u201336 (2018).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"3713_CR25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.wjorl.2018.04.004","volume":"4","author":"A Hu","year":"2018","unstructured":"Hu, A., Hillel, A., Zhao, W. & Meyer, T. Anxiety and depression in spasmodic dysphonia patients. World J. Otorhinolaryngol. Head Neck Surg. 4, 110\u2013116 (2018).","journal-title":"World J. Otorhinolaryngol. Head Neck Surg."},{"key":"3713_CR26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp-2018-319290","volume":"90","author":"AM Blumenfeld","year":"2019","unstructured":"Blumenfeld, A. M. et al. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J. Neurol. Neurosurg. Psychiatry 90, 353\u2013360 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"3713_CR27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10072-019-3719-9","volume":"40","author":"D Ceylan","year":"2019","unstructured":"Ceylan, D., Erer, S., Zarifo\u011flu, M., T\u00fcrke\u015f, N. & \u00d6zkaya, G. Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. Neurol. Sci. 40, 725\u2013731 (2019).","journal-title":"Neurol. Sci."},{"key":"3713_CR28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jocn.2020.07.075","volume":"80","author":"F d'Onofrio","year":"2020","unstructured":"d\u2019Onofrio, F. et al. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study. J. Clin. Neurosci. 80, 152\u2013155 (2020).","journal-title":"J. Clin. Neurosci."},{"key":"3713_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-021-01601-9","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Botulinum toxin A improves psychological distress in patients with hemifacial spasm. Acta Neurol. Belg. https:\/\/doi.org\/10.1007\/s13760-021-01601-9 (2021).","journal-title":"Acta Neurol. Belg."},{"key":"3713_CR30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2012.06.008","volume":"234","author":"C Holzmann","year":"2012","unstructured":"Holzmann, C. et al. Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats. Behav. Brain Res. 234, 107\u2013116 (2012).","journal-title":"Behav. Brain Res."},{"key":"3713_CR31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-021-01254-2","volume":"22","author":"WJ Chen","year":"2021","unstructured":"Chen, W. J. et al. Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice. J. Headache Pain 22, 38 (2021).","journal-title":"J. Headache Pain"},{"key":"3713_CR32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2021.06.071","volume":"569","author":"A Yesudhas","year":"2021","unstructured":"Yesudhas, A. et al. BOTOX counteracts the innate anxiety-related behaviours in correlation with increased activities of key antioxidant enzymes in the hippocampus of ageing experimental mice. Biochem. Biophys. Res. Commun. 569, 54\u201360 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3713_CR33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4088\/JCP.08r04516blu","volume":"71","author":"M Sinyor","year":"2010","unstructured":"Sinyor, M. et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J. Clin. Psychiatry 71, 270\u2013279 (2010).","journal-title":"J. Clin. Psychiatry"},{"key":"3713_CR34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/da.22433","volume":"32","author":"BR Rutherford","year":"2015","unstructured":"Rutherford, B. R. et al. Influence of study design on treatment response in anxiety disorder clinical trials. Depress. Anxiety 32, 944\u2013957 (2015).","journal-title":"Depress. Anxiety"},{"key":"3713_CR35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3163\/1536-5050.95.2.224","volume":"95","author":"V Craigle","year":"2007","unstructured":"Craigle, V. MedWatch: The FDA safety information and adverse event reporting program. J. Med. Libr. Assoc. 95, 224\u2013225 (2007).","journal-title":"J. Med. Libr. Assoc."},{"key":"3713_CR36","doi-asserted-by":"crossref","first-page":"19199","DOI":"10.1038\/s41598-020-76258-0","volume":"10","author":"IV Cohen","year":"2020","unstructured":"Cohen, I. V., Makunts, T., Moumedjian, T., Issa, M. A. & Abagyan, R. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. Sci. Rep. 10, 19199 (2020).","journal-title":"Sci. Rep."},{"key":"3713_CR37","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/s41598-021-85389-x","volume":"11","author":"IV Cohen","year":"2021","unstructured":"Cohen, I. V., Makunts, T., Abagyan, R. & Thomas, K. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci. Rep. 11, 5997 (2021).","journal-title":"Sci. Rep."},{"key":"3713_CR38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc, J. L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72, 905\u2013908 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3713_CR39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.0006-341X.1999.00597.x","volume":"55","author":"A Agresti","year":"1999","unstructured":"Agresti, A. On logit confidence intervals for the odds ratio with small samples. Biometrics 55, 597\u2013602 (1999).","journal-title":"Biometrics"},{"key":"3713_CR40","doi-asserted-by":"crossref","first-page":"584416","DOI":"10.3389\/fpsyt.2021.584416","volume":"12","author":"Y Li","year":"2021","unstructured":"Li, Y., Liu, T. & Luo, W. Botulinum neurotoxin therapy for depression: Therapeutic mechanisms and future perspective. Front. Psychiatry 12, 584416 (2021).","journal-title":"Front. Psychiatry"},{"key":"3713_CR41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/head.13074","volume":"57","author":"AM Blumenfeld","year":"2017","unstructured":"Blumenfeld, A. M. et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: Guidance on achieving optimal outcomes. Headache 57, 766\u2013777 (2017).","journal-title":"Headache"},{"key":"3713_CR42","volume-title":"Facial Action Coding System: A Technique for the Measurement of Facial Movement","author":"P Ekman","year":"1978","unstructured":"Ekman, P. & Friesen, W. V. Facial Action Coding System: A Technique for the Measurement of Facial Movement (Consulting Psychologists Press, 1978)."},{"key":"3713_CR43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3341\/kjo.2015.29.2.115","volume":"29","author":"Y Sung","year":"2015","unstructured":"Sung, Y., Nam, S. M. & Lew, H. Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm. Korean J. Ophthalmol. 29, 115\u2013120 (2015).","journal-title":"Korean J. Ophthalmol."},{"key":"3713_CR44","doi-asserted-by":"crossref","first-page":"511746","DOI":"10.3389\/fpsyg.2021.511746","volume":"12","author":"C Scheer","year":"2021","unstructured":"Scheer, C., Kubowitsch, S., Dendorfer, S. & Jansen, P. Happy enough to relax? How positive and negative emotions activate different muscular regions in the back - an explorative study. Front. Psychol. 12, 511746 (2021).","journal-title":"Front. Psychol."},{"key":"3713_CR45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1545968320905799","volume":"34","author":"S Khosravani","year":"2020","unstructured":"Khosravani, S., Buchanan, J., Johnson, M. D. & Konczak, J. Effect of neck botulinum neurotoxin injection on proprioception and somatosensory-motor cortical processing in cervical dystonia. Neurorehabil. Neural Repair 34, 309\u2013320 (2020).","journal-title":"Neurorehabil. Neural Repair"},{"key":"3713_CR46","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s13555-020-00439-y","volume":"10","author":"SZ Klein","year":"2020","unstructured":"Klein, S. Z., Hull, M., Gillard, K. K. & Peterson-Brandt, J. Treatment patterns, depression, and anxiety among US patients diagnosed with hyperhidrosis: a retrospective cohort study. Dermatol. Ther. 10, 1299\u20131314 (2020).","journal-title":"Dermatol. Ther."},{"key":"3713_CR47","doi-asserted-by":"crossref","first-page":"00240","DOI":"10.2340\/00015555-3598","volume":"100","author":"JK Kristensen","year":"2020","unstructured":"Kristensen, J. K. et al. Anxiety and depression in primary hyperhidrosis: an observational study of 95 consecutive Swedish outpatients. Acta Derm. Venereol. 100, 00240 (2020).","journal-title":"Acta Derm. Venereol."},{"key":"3713_CR48","doi-asserted-by":"crossref","first-page":"00044","DOI":"10.2340\/00015555-3598","volume":"100","author":"JK Kristensen","year":"2020","unstructured":"Kristensen, J. K., Vestergaard, D. G., Swartling, C. & Bygum, A. Association of primary hyperhidrosis with depression and anxiety: A systematic review. Acta Derm. Venereol. 100, 00044 (2020).","journal-title":"Acta Derm. Venereol."},{"key":"3713_CR49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v67n0105","volume":"67","author":"KM Connor","year":"2006","unstructured":"Connor, K. M., Cook, J. L. & Davidson, J. R. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. J. Clin. Psychiatry 67, 30\u201336 (2006).","journal-title":"J. Clin. Psychiatry"},{"key":"3713_CR50","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/luts.12395","volume":"13","author":"R Chess-Williams","year":"2021","unstructured":"Chess-Williams, R., McDermott, C., Sellers, D. J., West, E. G. & Mills, K. A. Chronic psychological stress and lower urinary tract symptoms. Low Urin. Tract Symptoms 13, 414\u2013424 (2021).","journal-title":"Low Urin. Tract Symptoms"},{"key":"3713_CR51","first-page":"247","volume":"11","author":"N Gholami","year":"2017","unstructured":"Gholami, N., Sabzvari, B. H., Razzaghi, A. & Salah, S. Effect of stress, anxiety and depression on unstimulated salivary flow rate and xerostomia. J. Dent. Res. Dent. Clin. Dent. Prospects 11, 247\u2013252 (2017).","journal-title":"J. Dent. Res. Dent. Clin. Dent. Prospects"},{"key":"3713_CR52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.toxicon.2008.12.026","volume":"54","author":"M Caleo","year":"2009","unstructured":"Caleo, M. & Schiavo, G. Central effects of tetanus and botulinum neurotoxins. Toxicon 54, 593\u2013599 (2009).","journal-title":"Toxicon"},{"key":"3713_CR53","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1523\/JNEUROSCI.2618-11.2011","volume":"31","author":"L Restani","year":"2011","unstructured":"Restani, L. et al. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT\/A). J. Neurosci. 31, 15650\u201315659 (2011).","journal-title":"J. Neurosci."},{"key":"3713_CR54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.toxicon.2015.07.013","volume":"107","author":"M Hallett","year":"2015","unstructured":"Hallett, M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. Toxicon 107, 64\u201367 (2015).","journal-title":"Toxicon"},{"key":"3713_CR55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/toxins11010021","volume":"11","author":"D Weise","year":"2019","unstructured":"Weise, D., Weise, C. M. & Naumann, M. Central effects of botulinum neurotoxin-evidence from human studies. Toxins 11, 21 (2019).","journal-title":"Toxins"},{"key":"3713_CR56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/toxins13020155","volume":"13","author":"P Hok","year":"2021","unstructured":"Hok, P., Veverka, T., Hlu\u0161t\u00edk, P., Nevrl\u00fd, M. & Ka\u0148ovsk\u00fd, P. The central effects of botulinum toxin in dystonia and spasticity. Toxins 13, 155 (2021).","journal-title":"Toxins"},{"key":"3713_CR57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00207454.2011.623807","volume":"122","author":"R Opavsk\u00fd","year":"2012","unstructured":"Opavsk\u00fd, R., Hlu\u0161t\u00edk, P., Otruba, P. & Ka\u0148ovsk\u00fd, P. Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: an fMRI study. Int. J. Neurosci. 122, 45\u201352 (2012).","journal-title":"Int. J. Neurosci."},{"key":"3713_CR58","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2169\/internalmedicine.55.5843","volume":"55","author":"A Kikuchi","year":"2016","unstructured":"Kikuchi, A. et al. Brain metabolic changes of cervical dystonia with spinocerebellar ataxia type 1 after botulinum toxin therapy. Intern. Med. 55, 1919\u20131922 (2016).","journal-title":"Intern. Med."},{"key":"3713_CR59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse, D. C. et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: Results of the migraine in America symptoms and treatment (MAST) study. J. Headache Pain 21, 23 (2020).","journal-title":"J. Headache Pain"},{"key":"3713_CR60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11940-017-0475-0","volume":"19","author":"KE Green","year":"2017","unstructured":"Green, K. E., Rastall, D. & Eggenberger, E. Treatment of blepharospasm\/hemifacial spasm. Curr. Treat. Options Neurol. 19, 41 (2017).","journal-title":"Curr. Treat. Options Neurol."},{"key":"3713_CR61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/15622975.2016.1181783","volume":"17","author":"B Bandelow","year":"2016","unstructured":"Bandelow, B. et al. Biological markers for anxiety disorders, OCD and PTSD\u2014A consensus statement. Part I: Neuroimaging and genetics. World J. Biol. Psychiatry 17, 321\u2013365 (2016).","journal-title":"World J. Biol. Psychiatry"},{"key":"3713_CR62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2016.1190867","volume":"18","author":"B Bandelow","year":"2017","unstructured":"Bandelow, B. et al. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J. Biol. Psychiatry 18, 162\u2013214 (2017).","journal-title":"World J. Biol. Psychiatry"},{"key":"3713_CR63","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/biom11060823","volume":"11","author":"G \u0160imi\u0107","year":"2021","unstructured":"\u0160imi\u0107, G. et al. Understanding emotions: Origins and roles of the amygdala. Biomolecules 11, 823 (2021).","journal-title":"Biomolecules"},{"key":"3713_CR64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/cercor\/bhn104","volume":"19","author":"A Hennenlotter","year":"2009","unstructured":"Hennenlotter, A. et al. The link between facial feedback and neural activity within central circuitries of emotion: New insights from botulinum toxin-induced denervation of frown muscles. Cereb. Cortex 19, 537\u2013542 (2009).","journal-title":"Cereb. Cortex"},{"key":"3713_CR65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-5380-4-11","volume":"4","author":"MJ Kim","year":"2014","unstructured":"Kim, M. J. et al. Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: Preliminary findings from an A-B-A design. Biol. Mood Anxiety Disord. 4, 11 (2014).","journal-title":"Biol. Mood Anxiety Disord."},{"key":"3713_CR66","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi, Y. M. & Hansen, R. A. Empirical estimation of under-reporting in the U.S. food and drug administration adverse event reporting system (FAERS). Expert. Opin. Drug Saf. 16, 761\u2013767 (2017).","journal-title":"Expert. Opin. Drug Saf."},{"key":"3713_CR67","doi-asserted-by":"crossref","first-page":"e25818","DOI":"10.7554\/eLife.25818","volume":"6","author":"M Maciejewski","year":"2017","unstructured":"Maciejewski, M. et al. Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. Elife 6, e25818 (2017).","journal-title":"Elife"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03713-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:35:40Z","timestamp":1670092540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03713-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03713-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.W. and T.H.C.K. have consulted for and received honoraria from Allergan\/Abbvie pharmaceuticals. Other authors declare no conflict of financial or non-financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24173"}}